FDA Drug · D-0051-2021

Catapres (clonidine hydrochloride, USP) 0.1 mg, tablet, 100-count bottle, Rx only, Dist. by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877, Made in Germany, NDC, 0597-0006-01

Class II · Terminated

An extraneous peak was observed for dissolution testing.

Affected lots / codes — check yours against thisLot # 761544, 859015, EXP Jan 2021, 861346, 956626, EXP Jan 2022

Recalling firm: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
Classification: Class II (temporary or reversible harm possible)
Status: Terminated
Quantity: 13,270 bottles/100 tablets each
Distribution: Distributed Nationwide in the USA and Puerto Rico
Recall initiated: October 5, 2020
Classified: October 26, 2020
Terminated: September 29, 2021
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0051-2021%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →